首页> 外文期刊>American journal of medical genetics, Part A >Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III
【24h】

Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III

机译:亚洲印度糖苷酶突变型糖原储存疾病III型磷酸溶酶突变

获取原文
获取原文并翻译 | 示例
           

摘要

Glycogen storage disease type III (GSD III) is a rare autosomal recessive inborn error of glycogen degradation pathway due to deficiency or reduced activity of glycogen debranching enzyme (GDE) that results in accumulation of abnormal glycogen in the liver, muscle, and heart. The cardinal hallmarks are hepatomegaly, fasting hypoglycemia, seizures, growth retardation, progressive skeletal myopathy, and cardiomyopathy in few. To date, 258 mutations in amyloglucosidase (AGL) gene have been identified worldwide. However, the mutation spectrum in the Asian Indian region is yet to be well characterized. We investigated 24 patients of Asian origin from 21 unrelated families with a provisional diagnosis of GSD III based on clinical and biochemical criteria. Molecular diagnosis was assessed by bidirectional sequencing and the impact of novel missense variants on the tertiary (three-dimensional) structure of GDE was evaluated by molecular modeling approach. Eighteen different pathogenic variants were identified, out of which 78% were novel. Novel variants included five nonsense, three small duplications and two small deletions, a splice site variant, and three missense variants. Variations in Exons 4, 14, 19, 24, 27, and 33 accounted for 61% of the total pathogenic variants identified and Allele p.Gly798Alafs*3 showed a high allele frequency of 11%. Molecular modeling study of novel pathogenic missense variants indicated the probable underlying molecular mechanism of adverse impact of variations on the structure and catalytic function of human GDE. Our study is the first large study on GSD III from the Asian subcontinent, which further expands the mutation spectrum of AGL.
机译:糖原储存疾病III型(GSD III)是糖原降解途径的稀有常染色体隐性天生误差,导致糖原脱枝酶(GDE)的活性降低,这导致肝脏,肌肉和心脏的异常糖原的积累。红衣主教标志是肝肿大,禁食低血糖,癫痫发作,生长迟缓,进步性骨骼肌病,少数。迄今为止,在全球范围内鉴定了淀粉葡糖苷酶(AGL)基因中的258个突变。然而,亚洲印第安地区的突变谱尚未表征。我们根据临床和生化标准调查了21名无关家庭的24名亚洲亚洲患者,临时诊断GSD III。通过双向测序评估分子诊断,并通过分子建模方法评估GDE的第三(三维)结构对GDE的第三次(三维)结构的影响。鉴定了18种不同的致病变体,其中78%是新的。新型变体包括五个废话,三个小重复和两个小缺失,拼接位点变体和三个畸形变种。外显子4,14,19,24,27和33的变化占鉴定的总致病变体的61%,并且等位基因P.Gly798AlaFs * 3显示出高的等位基因频率为11%。新型致病畸变变体的分子建模研究表明了人GDE结构和催化功能的变化不利影响的可能性分子机制。我们的研究是来自亚洲次大陆的第III的第一个大型研究,这进一步扩展了AGL的突变谱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号